Concentrated Saline Infusions and Increased Dietary Sodium With Diuretics for Heart Failure With Kidney Dysfunction

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE2

Total Enrollment

11 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-11-30

Study Completion Date

2008-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

At present the standard management of fluid overload in patients with congestive heart failure (CHF) involves limiting the intake of salt and water while administering high dose diuretics, often at the cost of deteriorating kidney function. However, another group of researchers has previously shown that intravenously infusing small volumes of concentrated saline during diuretic dosing and liberalizing dietary salt intake while continuing to limit water consumption resulted in improved fluid removal in CHF patients. Furthermore, less deterioration in kidney function, shorter hospitalizations, reduced readmission rates, and even reduced mortality were observed. The present study will examine this novel therapy in a population of 60 patients with underlying severe CHF and kidney dysfunction hospitalized for the management of fluid overload. Half of these patients will receive investigational treatment with concentrated salt infusions and liberalized salt consumption during diuretic therapy. All patients will otherwise receive the standard therapies for heart failure, including restrictions on water consumption. This study will attempt to verify the improvements in clinical endpoints previously described and define the mechanisms of enhanced fluid removal.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Safety and Efficacy of Low Dose Hypertonic Saline Solution and High Dose Furosemide for Congestive Heart Failure

NCT01028170

Congestive Heart Failure Renal Insufficiency

COMPLETED PHASE3

Natriuresis-Guided Diuretic Therapy in Patients With Acute Heart Failure With Reduced Ejection Fraction and Chronic Kidney Disease

NCT06203236

Acute Heart Failure Chronic Kidney Diseases

NOT_YET_RECRUITING PHASE4

Sodium-restricted Diets and Symptoms in End Stage Renal Disease: An RCT

NCT02778516

ESRD

COMPLETED NA

Urine Sodium-Driven Diuretic Adjustment Strategy in Acute Decompensated Heart Failure

NCT07263035

Heart Failure Heart Failure - NYHA II - IV Heart Failure Acute +1 more

NOT_YET_RECRUITING PHASE4

Impact of Hypertonic Saline Solution on Acute Decompensated Heart Failure

NCT05298098

Acute Decompensated Heart Failure

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Congestive Heart Failure Renal Insufficiency

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Group Type PLACEBO_COMPARATOR

Normal saline, then oral placebo capsule

Intervention Type DRUG

20mL normal saline infusion X 30min BID dosed simultaneously with IV bolus furosemide BID (latter dose per treating physician) PLUS 2gm sodium diet PLUS 1.5L fluid restriction. After switch to oral diuretic, begin oral placebo capsule BID, dosed with loop diuretic (dose per treating physician) PLUS 2gm sodium diet PLUS 1.5L fluid restriction.

2

Group Type ACTIVE_COMPARATOR

Hypertonic saline, then oral sodium chloride

Intervention Type DRUG

2mL/kg hypertonic saline (4.4% NaCl if serum sodium \</=135, else 2.8% NaCl) infused over 30min BID and dosed simultaneously with IV bolus furosemide BID (latter dose per treating physician) until patient is switched to oral loop diuretic. After switch to oral diuretic, subject will receive oral 0.75gm sodium (NaCL) capsule dosed BID with loop diuretic (latter dose per treating physician) until 60d after discharge.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Hypertonic saline, then oral sodium chloride

2mL/kg hypertonic saline (4.4% NaCl if serum sodium \</=135, else 2.8% NaCl) infused over 30min BID and dosed simultaneously with IV bolus furosemide BID (latter dose per treating physician) until patient is switched to oral loop diuretic. After switch to oral diuretic, subject will receive oral 0.75gm sodium (NaCL) capsule dosed BID with loop diuretic (latter dose per treating physician) until 60d after discharge.

Intervention Type DRUG

Normal saline, then oral placebo capsule

20mL normal saline infusion X 30min BID dosed simultaneously with IV bolus furosemide BID (latter dose per treating physician) PLUS 2gm sodium diet PLUS 1.5L fluid restriction. After switch to oral diuretic, begin oral placebo capsule BID, dosed with loop diuretic (dose per treating physician) PLUS 2gm sodium diet PLUS 1.5L fluid restriction.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adult patients (age ≥18) admitted with CHF exacerbation with NYHA Class III-IV symptoms at screening.
* Left ventricular ejection fraction \</= 45%, as determined by previous echocardiogram, left ventricular angiogram, or thallium myocardial imaging.
* Estimated GFR \<60 ml/min/1.7m² with significant prerenal physiology as judged by prior documented volume mediated changes in renal function, a fractional excretion of urea \<35%, or a fractional excretion of sodium \<1%. For GFR 30-60: must have serum sodium \</= 135 mEq/L OR large home diuretic dose (total daily loop diuretic dose \>/= 120 mg/d in furosemide equivalents OR concomitant thiazide use). For GFR \<30: no additional criteria needed.

Exclusion Criteria

* Admit estimated GFR \< 15mL/min or predicted need for chronic hemodialysis within the next 60 days.
* Cause of acute kidney injury other than prerenal physiology.
* No loop diuretic prior to admission or loop diuretic initiated within the 2 wks prior to admission.
* Medicine or dietary noncompliance expected to prevent successful study participation.
* \> 36hrs since presentation to screening.
* Serum Na \> 145 mEq/L OR \< 120 mEq/L at screening.
* Systolic blood pressure \> 180 mmHg at screening.
* Presentation with acute coronary syndrome OR left heart catheterization planned at screening.
* Current or impending respiratory failure at screening.
* Current calcineurin inhibitor or nesiritide use.
* Nephrotic-range proteinuria.
* Clinical evidence for the presence of cirrhosis with bilirubin \>/= 2mg/dL or international normalized ratio (not on coumadin) \>/= 1.7.
* Presence of another active medical issue which may prolong hospital admission or delay aggressive CHF therapy.
* Participation in another interventional study.
* Pregnancy.
* Prisoners.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No